Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations

Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility.

Rational Design and Selection of Angiotensinogen-Targeting siRNA Candidates for the Treatment of Hypertension

This framework represents an initial computational step toward developing long-acting RNA interference therapies for hypertension and provides a focused set of AGT-targeting siRNA candidates for future evaluation of off-target effects, delivery efficiency, target accessibility, and gene-silencing activity.

Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications

This article highlights the potential for personalized aquaretic therapy and identifies critical safety and monitoring protocols necessary for optimizing clinical outcomes by integrating structural, metabolic, and genetic data.

From Peptides to Aliskiren: The Evolution of Direct Renin Inhibitors in Hypertension Therapy.

Hypertension remains a major global health concern, significantly contributing to the burden of cardiovascular, renal, and cerebrovascular diseases. Conventional pharmacological interventions include calcium channel blockers, beta-blockers, diuretics, Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin Receptor (AR) antagonists. However, these therapies often present limitations, particularly in patients with comorbid conditions such as diabetes, where end-organ damage persists despite Renin-Angiotensin-Aldosterone System (RAAS) blockade. A promising alternative lies in targeting the RAAS at its origin-renin, the rate-limiting enzyme responsible for converting angiotensinogen to angiotensin I. Direct Renin Inhibitors (DRIs) offer a mechanistically distinct approach by inhibiting renin's catalytic activity, thereby attenuating downstream RAAS activation. The development of DRIs has evolved through successive generations, beginning with peptide-based inhibitors, such as pepstatin, which demonstrated limited bioavailability and metabolic stability. Subsequent peptidomimetic compounds improved pharmacokinetic profiles but retained structural constraints. The advent of non-peptide DRIs, exemplified by aliskiren (Tekturna), marked a significant breakthrough. Developed via structure-based drug design and molecular modelling, aliskiren exhibits high specificity and oral bioavailability, earning FDA approval in 2007. Despite encouraging preclinical efficacy, clinical trials of aliskiren have yielded mixed results, particularly regarding long-term outcomes and safety in combination therapies. These findings underscore the complexity of RAAS modulation and the need for continued investigation into DRI pharmacodynamics, tissue-specific effects, and patient stratification. This review focuses on the historical trajectory and molecular refinement of DRIs, highlighting the interplay between structural innovation and therapeutic potential in the quest for more effective hypertension management.

Emerging Pharmacological Therapies for Hypertension.

This review provides a general overview of the physiological effects and pharmacokinetic properties that affect the absorption, distribution, metabolism, and elimination of recently developed antihypertensive drugs, such as fimasartan, azilsartan, zilebesiran, aprocitentan, and esaxerenone. It provides an opportunity to understand the pharmacologic properties of drugs like esaxerenone, a non-steroidal selective mineralocorticoid receptor antagonist; aprocitentan, a dual endothelin receptor antagonist; and zilebesiran, a small interfering RNA (siRNA) therapeutic that inhibits hepatic angiotensinogen synthesis. Mechanistic differences among these agents are also highlighted; for instance, fimasartan and azilsartan inhibit the angiotensin II receptor, whereas other medications alter mineralocorticoid activity or endothelial pathways. The review further discusses the clinical implications of these mechanisms in hypertension management and supports informed therapeutic decisionmaking by providing a detailed understanding of the pharmacological and mechanistic profiles of these emerging antihypertensive therapies.

Possibilities of antihypertensive therapy with a drug based on small interfering ribonucleic acid

Inadequate blood pressure control is one of the main causes of cardiovascular complications. This problem remains pressing, in part due to low adherence to therapy associated with complex regimens. This has led to attempts to find new solutions, including the development of agents that do not require frequent administration and can be used to enhance the antihypertensive effect in addition to existing oral medications. Currently, the potential for treating hypertension with an injectable drug based on small interfering ribonucleic acid called zilebesiran is being actively studied. Its antihypertensive effect is associated with the suppression of hepatic angiotensinogen production and a corresponding reduction in angiotensin II levels. In a clinical trial, a single subcutaneous administration of zilebesiran resulted in a significant reduction in blood pressure, with the effect lasting for up to 6 months. This article reviews the literature on this new antihypertensive drug.